IMVT's Trial Troubles: When Bad News Creates Good Premium
Immunovant just served up a textbook example of why biotech volatility creates Atlas opportunities. The stock dropped 2.4% after their batoclimab treatment missed late-stage endpoints for eye disease
Atlas Portfolio results referenced in this post are produced in a simulation environment using EOD market data and contract pricing. They are not records of trades placed in a brokerage account or executed with real capital, and individual results would vary based on fills, commissions, slippage, and account size. Tiblio is a software platform for finding and executing options trade ideas. We are not a registered investment advisor or broker-dealer. Nothing in this post is financial advice. Options trading involves substantial risk of loss. Past or simulated performance does not guarantee future results.